PrimeC Combo Drug Shows Early Promise Against Alzheimer's Biomarkers
NeuroSense's oral drug combination shifted key Alzheimer's proteins in a small Phase 2 trial, with no serious safety concerns reported.
Summary
NeuroSense has released early findings from a small Phase 2 trial testing PrimeC — an oral pill combining the antibiotic ciprofloxacin and the anti-inflammatory celecoxib — in Alzheimer's disease patients. The study enrolled eight participants, with three completing 12 months of follow-up. Blood and spinal fluid analyses showed changes in key Alzheimer's-related proteins, including tau, amyloid-beta, and TDP-43, moving in directions consistent with the drug's proposed mechanism. Markers of inflammation and oxidative stress also shifted favorably. No serious side effects were reported. The company stresses these findings are exploratory and the sample size is too small to draw firm conclusions, but plans to use this data to design a larger, more definitive trial.
Detailed Summary
Alzheimer's disease remains one of the most devastating and treatment-resistant conditions in aging medicine, making any credible early-stage signal worth attention. NeuroSense has now reported preliminary biomarker findings from its Phase 2 RoAD trial of PrimeC, a fixed-dose oral combination of ciprofloxacin — a widely used antibiotic — and celecoxib, a common anti-inflammatory drug. The rationale is that Alzheimer's involves overlapping pathways including neuroinflammation, oxidative stress, and protein aggregation, which a dual-mechanism drug might better address.
The trial enrolled eight participants in a randomized, double-blind, placebo-controlled design. Three participants completed the full 12-month follow-up with cerebrospinal fluid and plasma samples collected at three time points. In these samples, researchers observed changes in core Alzheimer's hallmark proteins: total tau, phospho-tau species, and the amyloid-beta 42/40 ratio — a key diagnostic and disease-activity marker. Notably, alterations were also seen in alpha-synuclein and TDP-43, proteins linked to broader neurodegeneration, suggesting PrimeC may affect multiple disease pathways simultaneously.
Additionally, biomarkers of oxidative stress and neuroinflammation shifted in directions consistent with the drug's proposed mechanism. These patterns echo findings from NeuroSense's ALS program, where PrimeC has shown similar multi-target effects, lending some biological plausibility to the results.
From a safety standpoint, the trial reported no serious adverse events and no new safety signals — a meaningful baseline for any drug targeting an elderly population. The favorable tolerability profile is particularly important given that Alzheimer's patients often carry additional health vulnerabilities.
Critically, NeuroSense itself cautions that these are exploratory findings from a very small sample. The results are not statistically powered and may not be predictive of outcomes in larger populations. The company intends to use these data to inform the design of a properly powered future trial. Longevity-focused readers should track this space but await larger, confirmatory studies before drawing clinical conclusions.
Key Findings
- PrimeC shifted tau and amyloid-beta 42/40 ratio in directions consistent with Alzheimer's disease modification.
- Alpha-synuclein and TDP-43 protein levels also changed, suggesting broad neurodegeneration pathway involvement.
- Biomarkers of oxidative stress and inflammation moved favorably, aligning with the drug's multi-target design.
- No serious adverse events were recorded over 12 months in this elderly Alzheimer's population.
- Results are exploratory; only 3 of 8 participants had analyzable 12-month biofluid samples.
Methodology
This is a news report summarizing early Phase 2 clinical trial results disclosed by NeuroSense, a commercial sponsor. The underlying study (NST-AD-001) is randomized, double-blind, and placebo-controlled, but extremely small — only three participants contributed analyzable 12-month samples. No peer-reviewed publication was cited.
Study Limitations
The sample size of three analyzable participants makes statistical significance impossible; findings are purely hypothesis-generating. Results are company-disclosed and not yet peer-reviewed or independently validated. Readers should await publication in a peer-reviewed journal and results from a larger powered trial before drawing conclusions.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: